News for Iterum Therapeutics plc (ITRM)

**media[651578]**

Iterum Therapeutics (ITRM) has secured an extension from Pfizer regarding the $20 million regulatory milestone payment, now due by October 25, 2029. Originally

Iterum Therapeutics (ITRM) and Pfizer agree to extend a $20M debt payment deadline to October 2029. The interest rate on the debt will increase from 8%

DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc ( ITRM) (the ”œCompany” or ”œIterum”), a company focused on delivering next

Total Operating Expenses: $3.7 million in Q1 2025, down from $6.2 million in Q1 2024.R&D Costs: $600,000 in Q1 2025, compared to $4 million in Q1 2024.G&A Cost

May 13, 2025 / 12:30PM GMTOperator Hello, everyone, and thank you for joining the Iterum Therapeutics plc first-quarter 2025 earnings and business update call.

DUBLIN, Ireland and CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc ( ITRM) (Company), a company focused on delivering next generation oral

DUBLIN, Ireland and CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc ( ITRM) (the Company), a company focused on delivering next generation

Iterum Therapeutics (ITRM) has finalized an agreement with a single institutional investor to sell 5,555,556 ordinary shares at $0.90 each, in a registered dire

DUBLIN, Ireland and CHICAGO, April 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc ( ITRM) (the Company), a company focused on delivering next generation

Maine-based Synergy CHC Corp. (SNYR) is up over 139 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) made a significant move by acquiring an additional 105,158 shares of Iterum Therapeutics PLC (I

Operator: Hello, everyone. And welcome to the Iterum Therapeutics plc Fourth Quarter and Full Year 2024 financial results. My name is Ezra, and I will be your coordinator today [Operator Instructions].

Total Operating Expenses (Q4 2024): $3.7 millionTotal Operating Expenses (Full Year 2024): $18.7 millionR&D Costs (Q4 2024): $1.3 millionR&D Costs (Full Year 2

Feb 07, 2025 / 01:30PM GMTOperator Hello, everyone, and welcome to the Iterum Therapeutics PLC Fourth-Quarter and Full Year 2024 Financial Results. My name is E

Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2024 Earnings Conference Call February 7, 2025 8:30 AM ETCompany ParticipantsLouise Barrett - SVP, Legal...

California-based Conduit Pharmaceuticals Inc. (CDT), a clinical-stage specialty biopharmaceutical company is up over 79 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

**media[534924]**

--ORLYNVAHTM Approved by FDA in Q4 2024”” --Extended Cash Runway-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Feb. 07, 2025